In HIBISCUS I and HIBISCUS II, two identically designed, multicenter, phase III, randomized, double-blind, placebo-controlled and active-controlled studies, Etrastuzumab given to patients with moderately to severely active ulcerative colitis who had not been treated with an anti-TNF agent, Etrastuzumab was superior to placebo in inducing remission in HIBISCUS I, but its performance was not superior to Adalimumab in both HIBISCUS I and HIBISCUS II trials [111], and it also performed similarly to Infliximab (tumor necrosis factor inhibitor) [112]. Here, TNF is linked to ulcerative colitis.